Global Non-selective PDE Inhibitors Market Growth 2026-2032
The global Non-selective PDE Inhibitors market size is predicted to grow from US$ 290 million in 2025 to US$ 398 million in 2032; it is expected to grow at a CAGR of 4.7% from 2026 to 2032.
Non-selective PDE inhibitors represent an earlier generation of phosphodiesterase inhibitors that act on multiple PDE isoenzymes simultaneously, thereby enhancing both cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) signaling pathways. Representative compounds include theophylline and Ibudilast, which have historically been used in the treatment of asthma, chronic obstructive pulmonary disease (COPD), cardiovascular conditions, and as central nervous system stimulants. Their upstream raw materials are primarily synthetic small molecules such as xanthine derivatives and methylxanthines, with supply chains concentrated among chemical and pharmaceutical intermediates manufacturers in Europe, North America, and Asia. Key suppliers include multinational API producers and specialized fine chemical companies.
On the downstream side, the major customers of non-selective PDE inhibitors are pharmaceutical firms and generic drug manufacturers, who market them as either prescription or over-the-counter medications. Additionally, due to compounds like caffeine being widely utilized in functional beverages and dietary supplements, clients also extend to food & beverage producers and nutraceutical companies. Despite being gradually replaced by more selective PDE inhibitors due to safety and efficacy considerations, non-selective PDE inhibitors retain a role in legacy therapies, cost-sensitive healthcare markets, and high-volume OTC applications, maintaining a stable but specialized demand base.
In 2024, the global average price of non-selective PDE inhibitors is approximately USD 0.053 per unit (where "unit" refers to the smallest packaged dosage form, such as a tablet, capsule, or vial), with total sales reaching about 5.245 billion units.
United States market for Non-selective PDE Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Non-selective PDE Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Non-selective PDE Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Non-selective PDE Inhibitors players cover Kyorin Holdings, Senju Pharmaceutical, Handok, Endo International, iNova Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
This Insight Report provides a comprehensive analysis of the global Non-selective PDE Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-selective PDE Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-selective PDE Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-selective PDE Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-selective PDE Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-selective PDE Inhibitors market by product type, application, key manufacturers and key regions and countries.
Non-selective PDE inhibitors represent an earlier generation of phosphodiesterase inhibitors that act on multiple PDE isoenzymes simultaneously, thereby enhancing both cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) signaling pathways. Representative compounds include theophylline and Ibudilast, which have historically been used in the treatment of asthma, chronic obstructive pulmonary disease (COPD), cardiovascular conditions, and as central nervous system stimulants. Their upstream raw materials are primarily synthetic small molecules such as xanthine derivatives and methylxanthines, with supply chains concentrated among chemical and pharmaceutical intermediates manufacturers in Europe, North America, and Asia. Key suppliers include multinational API producers and specialized fine chemical companies.
On the downstream side, the major customers of non-selective PDE inhibitors are pharmaceutical firms and generic drug manufacturers, who market them as either prescription or over-the-counter medications. Additionally, due to compounds like caffeine being widely utilized in functional beverages and dietary supplements, clients also extend to food & beverage producers and nutraceutical companies. Despite being gradually replaced by more selective PDE inhibitors due to safety and efficacy considerations, non-selective PDE inhibitors retain a role in legacy therapies, cost-sensitive healthcare markets, and high-volume OTC applications, maintaining a stable but specialized demand base.
In 2024, the global average price of non-selective PDE inhibitors is approximately USD 0.053 per unit (where "unit" refers to the smallest packaged dosage form, such as a tablet, capsule, or vial), with total sales reaching about 5.245 billion units.
United States market for Non-selective PDE Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Non-selective PDE Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Non-selective PDE Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Non-selective PDE Inhibitors players cover Kyorin Holdings, Senju Pharmaceutical, Handok, Endo International, iNova Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
Report Scope
LP Information, Inc. (LPI) ' newest research report, the “Non-selective PDE Inhibitors Industry Forecast” looks at past sales and reviews total world Non-selective PDE Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected Non-selective PDE Inhibitors sales for 2026 through 2032. With Non-selective PDE Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-selective PDE Inhibitors industry.This Insight Report provides a comprehensive analysis of the global Non-selective PDE Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-selective PDE Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-selective PDE Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-selective PDE Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-selective PDE Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-selective PDE Inhibitors market by product type, application, key manufacturers and key regions and countries.
Market Segmentation
Segmentation by Type:
- Theophylline
- Ibudilast
- Other
Segmentation by Application:
- Hospital
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Kyorin Holdings
- Senju Pharmaceutical
- Handok
- Endo International
- iNova Pharmaceuticals
- Alembic
- Mundipharma
- Mitsubishi Tanabe Pharma
- Glenmark Pharmaceuticals
- Reyoung Pharmaceutical
Key Questions Addressed in this Report
- What is the 10-year outlook for the global Non-selective PDE Inhibitors market?
- What factors are driving Non-selective PDE Inhibitors market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Non-selective PDE Inhibitors market opportunities vary by end market size?
- How does Non-selective PDE Inhibitors break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non-selective PDE Inhibitors Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Non-selective PDE Inhibitors by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Non-selective PDE Inhibitors by Country/Region, 2021, 2025 & 2032
2.2 Non-selective PDE Inhibitors Segment by Type
2.2.1 Theophylline
2.2.2 Ibudilast
2.2.3 Other
2.2.4 Non-selective PDE Inhibitors Sales by Type
2.2.4.1 Global Non-selective PDE Inhibitors Sales Market Share by Type (2021-2026)
2.2.4.2 Global Non-selective PDE Inhibitors Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Non-selective PDE Inhibitors Sale Price by Type (2021-2026)
2.3 Non-selective PDE Inhibitors Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Others
2.3.4 Non-selective PDE Inhibitors Sales by Application
2.3.4.1 Global Non-selective PDE Inhibitors Sale Market Share by Application (2021-2026)
2.3.4.2 Global Non-selective PDE Inhibitors Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Non-selective PDE Inhibitors Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Non-selective PDE Inhibitors Breakdown Data by Company
3.1.1 Global Non-selective PDE Inhibitors Annual Sales by Company (2021-2026)
3.1.2 Global Non-selective PDE Inhibitors Sales Market Share by Company (2021-2026)
3.2 Global Non-selective PDE Inhibitors Annual Revenue by Company (2021-2026)
3.2.1 Global Non-selective PDE Inhibitors Revenue by Company (2021-2026)
3.2.2 Global Non-selective PDE Inhibitors Revenue Market Share by Company (2021-2026)
3.3 Global Non-selective PDE Inhibitors Sale Price by Company
3.4 Key Manufacturers Non-selective PDE Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non-selective PDE Inhibitors Product Location Distribution
3.4.2 Players Non-selective PDE Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NON-SELECTIVE PDE INHIBITORS BY GEOGRAPHIC REGION
4.1 World Historic Non-selective PDE Inhibitors Market Size by Geographic Region (2021-2026)
4.1.1 Global Non-selective PDE Inhibitors Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Non-selective PDE Inhibitors Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Non-selective PDE Inhibitors Market Size by Country/Region (2021-2026)
4.2.1 Global Non-selective PDE Inhibitors Annual Sales by Country/Region (2021-2026)
4.2.2 Global Non-selective PDE Inhibitors Annual Revenue by Country/Region (2021-2026)
4.3 Americas Non-selective PDE Inhibitors Sales Growth
4.4 APAC Non-selective PDE Inhibitors Sales Growth
4.5 Europe Non-selective PDE Inhibitors Sales Growth
4.6 Middle East & Africa Non-selective PDE Inhibitors Sales Growth
5 AMERICAS
5.1 Americas Non-selective PDE Inhibitors Sales by Country
5.1.1 Americas Non-selective PDE Inhibitors Sales by Country (2021-2026)
5.1.2 Americas Non-selective PDE Inhibitors Revenue by Country (2021-2026)
5.2 Americas Non-selective PDE Inhibitors Sales by Type (2021-2026)
5.3 Americas Non-selective PDE Inhibitors Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-selective PDE Inhibitors Sales by Region
6.1.1 APAC Non-selective PDE Inhibitors Sales by Region (2021-2026)
6.1.2 APAC Non-selective PDE Inhibitors Revenue by Region (2021-2026)
6.2 APAC Non-selective PDE Inhibitors Sales by Type (2021-2026)
6.3 APAC Non-selective PDE Inhibitors Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Non-selective PDE Inhibitors by Country
7.1.1 Europe Non-selective PDE Inhibitors Sales by Country (2021-2026)
7.1.2 Europe Non-selective PDE Inhibitors Revenue by Country (2021-2026)
7.2 Europe Non-selective PDE Inhibitors Sales by Type (2021-2026)
7.3 Europe Non-selective PDE Inhibitors Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non-selective PDE Inhibitors by Country
8.1.1 Middle East & Africa Non-selective PDE Inhibitors Sales by Country (2021-2026)
8.1.2 Middle East & Africa Non-selective PDE Inhibitors Revenue by Country (2021-2026)
8.2 Middle East & Africa Non-selective PDE Inhibitors Sales by Type (2021-2026)
8.3 Middle East & Africa Non-selective PDE Inhibitors Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Non-selective PDE Inhibitors
10.3 Manufacturing Process Analysis of Non-selective PDE Inhibitors
10.4 Industry Chain Structure of Non-selective PDE Inhibitors
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Non-selective PDE Inhibitors Distributors
11.3 Non-selective PDE Inhibitors Customer
12 WORLD FORECAST REVIEW FOR NON-SELECTIVE PDE INHIBITORS BY GEOGRAPHIC REGION
12.1 Global Non-selective PDE Inhibitors Market Size Forecast by Region
12.1.1 Global Non-selective PDE Inhibitors Forecast by Region (2027-2032)
12.1.2 Global Non-selective PDE Inhibitors Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Non-selective PDE Inhibitors Forecast by Type (2027-2032)
12.7 Global Non-selective PDE Inhibitors Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Kyorin Holdings
13.1.1 Kyorin Holdings Company Information
13.1.2 Kyorin Holdings Non-selective PDE Inhibitors Product Portfolios and Specifications
13.1.3 Kyorin Holdings Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Kyorin Holdings Main Business Overview
13.1.5 Kyorin Holdings Latest Developments
13.2 Senju Pharmaceutical
13.2.1 Senju Pharmaceutical Company Information
13.2.2 Senju Pharmaceutical Non-selective PDE Inhibitors Product Portfolios and Specifications
13.2.3 Senju Pharmaceutical Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Senju Pharmaceutical Main Business Overview
13.2.5 Senju Pharmaceutical Latest Developments
13.3 Handok
13.3.1 Handok Company Information
13.3.2 Handok Non-selective PDE Inhibitors Product Portfolios and Specifications
13.3.3 Handok Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Handok Main Business Overview
13.3.5 Handok Latest Developments
13.4 Endo International
13.4.1 Endo International Company Information
13.4.2 Endo International Non-selective PDE Inhibitors Product Portfolios and Specifications
13.4.3 Endo International Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Endo International Main Business Overview
13.4.5 Endo International Latest Developments
13.5 iNova Pharmaceuticals
13.5.1 iNova Pharmaceuticals Company Information
13.5.2 iNova Pharmaceuticals Non-selective PDE Inhibitors Product Portfolios and Specifications
13.5.3 iNova Pharmaceuticals Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 iNova Pharmaceuticals Main Business Overview
13.5.5 iNova Pharmaceuticals Latest Developments
13.6 Alembic
13.6.1 Alembic Company Information
13.6.2 Alembic Non-selective PDE Inhibitors Product Portfolios and Specifications
13.6.3 Alembic Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Alembic Main Business Overview
13.6.5 Alembic Latest Developments
13.7 Mundipharma
13.7.1 Mundipharma Company Information
13.7.2 Mundipharma Non-selective PDE Inhibitors Product Portfolios and Specifications
13.7.3 Mundipharma Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Mundipharma Main Business Overview
13.7.5 Mundipharma Latest Developments
13.8 Mitsubishi Tanabe Pharma
13.8.1 Mitsubishi Tanabe Pharma Company Information
13.8.2 Mitsubishi Tanabe Pharma Non-selective PDE Inhibitors Product Portfolios and Specifications
13.8.3 Mitsubishi Tanabe Pharma Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Mitsubishi Tanabe Pharma Main Business Overview
13.8.5 Mitsubishi Tanabe Pharma Latest Developments
13.9 Glenmark Pharmaceuticals
13.9.1 Glenmark Pharmaceuticals Company Information
13.9.2 Glenmark Pharmaceuticals Non-selective PDE Inhibitors Product Portfolios and Specifications
13.9.3 Glenmark Pharmaceuticals Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Glenmark Pharmaceuticals Main Business Overview
13.9.5 Glenmark Pharmaceuticals Latest Developments
13.10 Reyoung Pharmaceutical
13.10.1 Reyoung Pharmaceutical Company Information
13.10.2 Reyoung Pharmaceutical Non-selective PDE Inhibitors Product Portfolios and Specifications
13.10.3 Reyoung Pharmaceutical Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Reyoung Pharmaceutical Main Business Overview
13.10.5 Reyoung Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non-selective PDE Inhibitors Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Non-selective PDE Inhibitors by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Non-selective PDE Inhibitors by Country/Region, 2021, 2025 & 2032
2.2 Non-selective PDE Inhibitors Segment by Type
2.2.1 Theophylline
2.2.2 Ibudilast
2.2.3 Other
2.2.4 Non-selective PDE Inhibitors Sales by Type
2.2.4.1 Global Non-selective PDE Inhibitors Sales Market Share by Type (2021-2026)
2.2.4.2 Global Non-selective PDE Inhibitors Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Non-selective PDE Inhibitors Sale Price by Type (2021-2026)
2.3 Non-selective PDE Inhibitors Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Others
2.3.4 Non-selective PDE Inhibitors Sales by Application
2.3.4.1 Global Non-selective PDE Inhibitors Sale Market Share by Application (2021-2026)
2.3.4.2 Global Non-selective PDE Inhibitors Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Non-selective PDE Inhibitors Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Non-selective PDE Inhibitors Breakdown Data by Company
3.1.1 Global Non-selective PDE Inhibitors Annual Sales by Company (2021-2026)
3.1.2 Global Non-selective PDE Inhibitors Sales Market Share by Company (2021-2026)
3.2 Global Non-selective PDE Inhibitors Annual Revenue by Company (2021-2026)
3.2.1 Global Non-selective PDE Inhibitors Revenue by Company (2021-2026)
3.2.2 Global Non-selective PDE Inhibitors Revenue Market Share by Company (2021-2026)
3.3 Global Non-selective PDE Inhibitors Sale Price by Company
3.4 Key Manufacturers Non-selective PDE Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non-selective PDE Inhibitors Product Location Distribution
3.4.2 Players Non-selective PDE Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NON-SELECTIVE PDE INHIBITORS BY GEOGRAPHIC REGION
4.1 World Historic Non-selective PDE Inhibitors Market Size by Geographic Region (2021-2026)
4.1.1 Global Non-selective PDE Inhibitors Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Non-selective PDE Inhibitors Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Non-selective PDE Inhibitors Market Size by Country/Region (2021-2026)
4.2.1 Global Non-selective PDE Inhibitors Annual Sales by Country/Region (2021-2026)
4.2.2 Global Non-selective PDE Inhibitors Annual Revenue by Country/Region (2021-2026)
4.3 Americas Non-selective PDE Inhibitors Sales Growth
4.4 APAC Non-selective PDE Inhibitors Sales Growth
4.5 Europe Non-selective PDE Inhibitors Sales Growth
4.6 Middle East & Africa Non-selective PDE Inhibitors Sales Growth
5 AMERICAS
5.1 Americas Non-selective PDE Inhibitors Sales by Country
5.1.1 Americas Non-selective PDE Inhibitors Sales by Country (2021-2026)
5.1.2 Americas Non-selective PDE Inhibitors Revenue by Country (2021-2026)
5.2 Americas Non-selective PDE Inhibitors Sales by Type (2021-2026)
5.3 Americas Non-selective PDE Inhibitors Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-selective PDE Inhibitors Sales by Region
6.1.1 APAC Non-selective PDE Inhibitors Sales by Region (2021-2026)
6.1.2 APAC Non-selective PDE Inhibitors Revenue by Region (2021-2026)
6.2 APAC Non-selective PDE Inhibitors Sales by Type (2021-2026)
6.3 APAC Non-selective PDE Inhibitors Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Non-selective PDE Inhibitors by Country
7.1.1 Europe Non-selective PDE Inhibitors Sales by Country (2021-2026)
7.1.2 Europe Non-selective PDE Inhibitors Revenue by Country (2021-2026)
7.2 Europe Non-selective PDE Inhibitors Sales by Type (2021-2026)
7.3 Europe Non-selective PDE Inhibitors Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non-selective PDE Inhibitors by Country
8.1.1 Middle East & Africa Non-selective PDE Inhibitors Sales by Country (2021-2026)
8.1.2 Middle East & Africa Non-selective PDE Inhibitors Revenue by Country (2021-2026)
8.2 Middle East & Africa Non-selective PDE Inhibitors Sales by Type (2021-2026)
8.3 Middle East & Africa Non-selective PDE Inhibitors Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Non-selective PDE Inhibitors
10.3 Manufacturing Process Analysis of Non-selective PDE Inhibitors
10.4 Industry Chain Structure of Non-selective PDE Inhibitors
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Non-selective PDE Inhibitors Distributors
11.3 Non-selective PDE Inhibitors Customer
12 WORLD FORECAST REVIEW FOR NON-SELECTIVE PDE INHIBITORS BY GEOGRAPHIC REGION
12.1 Global Non-selective PDE Inhibitors Market Size Forecast by Region
12.1.1 Global Non-selective PDE Inhibitors Forecast by Region (2027-2032)
12.1.2 Global Non-selective PDE Inhibitors Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Non-selective PDE Inhibitors Forecast by Type (2027-2032)
12.7 Global Non-selective PDE Inhibitors Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Kyorin Holdings
13.1.1 Kyorin Holdings Company Information
13.1.2 Kyorin Holdings Non-selective PDE Inhibitors Product Portfolios and Specifications
13.1.3 Kyorin Holdings Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Kyorin Holdings Main Business Overview
13.1.5 Kyorin Holdings Latest Developments
13.2 Senju Pharmaceutical
13.2.1 Senju Pharmaceutical Company Information
13.2.2 Senju Pharmaceutical Non-selective PDE Inhibitors Product Portfolios and Specifications
13.2.3 Senju Pharmaceutical Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Senju Pharmaceutical Main Business Overview
13.2.5 Senju Pharmaceutical Latest Developments
13.3 Handok
13.3.1 Handok Company Information
13.3.2 Handok Non-selective PDE Inhibitors Product Portfolios and Specifications
13.3.3 Handok Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Handok Main Business Overview
13.3.5 Handok Latest Developments
13.4 Endo International
13.4.1 Endo International Company Information
13.4.2 Endo International Non-selective PDE Inhibitors Product Portfolios and Specifications
13.4.3 Endo International Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Endo International Main Business Overview
13.4.5 Endo International Latest Developments
13.5 iNova Pharmaceuticals
13.5.1 iNova Pharmaceuticals Company Information
13.5.2 iNova Pharmaceuticals Non-selective PDE Inhibitors Product Portfolios and Specifications
13.5.3 iNova Pharmaceuticals Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 iNova Pharmaceuticals Main Business Overview
13.5.5 iNova Pharmaceuticals Latest Developments
13.6 Alembic
13.6.1 Alembic Company Information
13.6.2 Alembic Non-selective PDE Inhibitors Product Portfolios and Specifications
13.6.3 Alembic Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Alembic Main Business Overview
13.6.5 Alembic Latest Developments
13.7 Mundipharma
13.7.1 Mundipharma Company Information
13.7.2 Mundipharma Non-selective PDE Inhibitors Product Portfolios and Specifications
13.7.3 Mundipharma Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Mundipharma Main Business Overview
13.7.5 Mundipharma Latest Developments
13.8 Mitsubishi Tanabe Pharma
13.8.1 Mitsubishi Tanabe Pharma Company Information
13.8.2 Mitsubishi Tanabe Pharma Non-selective PDE Inhibitors Product Portfolios and Specifications
13.8.3 Mitsubishi Tanabe Pharma Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Mitsubishi Tanabe Pharma Main Business Overview
13.8.5 Mitsubishi Tanabe Pharma Latest Developments
13.9 Glenmark Pharmaceuticals
13.9.1 Glenmark Pharmaceuticals Company Information
13.9.2 Glenmark Pharmaceuticals Non-selective PDE Inhibitors Product Portfolios and Specifications
13.9.3 Glenmark Pharmaceuticals Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Glenmark Pharmaceuticals Main Business Overview
13.9.5 Glenmark Pharmaceuticals Latest Developments
13.10 Reyoung Pharmaceutical
13.10.1 Reyoung Pharmaceutical Company Information
13.10.2 Reyoung Pharmaceutical Non-selective PDE Inhibitors Product Portfolios and Specifications
13.10.3 Reyoung Pharmaceutical Non-selective PDE Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Reyoung Pharmaceutical Main Business Overview
13.10.5 Reyoung Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Non-selective PDE Inhibitors Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Non-selective PDE Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Theophylline
Table 4. Major Players of Ibudilast
Table 5. Major Players of Other
Table 6. Global Non-selective PDE Inhibitors Sales by Type (2021-2026) & (K Units)
Table 7. Global Non-selective PDE Inhibitors Sales Market Share by Type (2021-2026)
Table 8. Global Non-selective PDE Inhibitors Revenue by Type (2021-2026) & ($ million)
Table 9. Global Non-selective PDE Inhibitors Revenue Market Share by Type (2021-2026)
Table 10. Global Non-selective PDE Inhibitors Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Non-selective PDE Inhibitors Sale by Application (2021-2026) & (K Units)
Table 12. Global Non-selective PDE Inhibitors Sale Market Share by Application (2021-2026)
Table 13. Global Non-selective PDE Inhibitors Revenue by Application (2021-2026) & ($ million)
Table 14. Global Non-selective PDE Inhibitors Revenue Market Share by Application (2021-2026)
Table 15. Global Non-selective PDE Inhibitors Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Non-selective PDE Inhibitors Sales by Company (2021-2026) & (K Units)
Table 17. Global Non-selective PDE Inhibitors Sales Market Share by Company (2021-2026)
Table 18. Global Non-selective PDE Inhibitors Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Non-selective PDE Inhibitors Revenue Market Share by Company (2021-2026)
Table 20. Global Non-selective PDE Inhibitors Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Non-selective PDE Inhibitors Producing Area Distribution and Sales Area
Table 22. Players Non-selective PDE Inhibitors Products Offered
Table 23. Non-selective PDE Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Non-selective PDE Inhibitors Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Non-selective PDE Inhibitors Sales Market Share Geographic Region (2021-2026)
Table 28. Global Non-selective PDE Inhibitors Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Non-selective PDE Inhibitors Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Non-selective PDE Inhibitors Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Non-selective PDE Inhibitors Sales Market Share by Country/Region (2021-2026)
Table 32. Global Non-selective PDE Inhibitors Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Non-selective PDE Inhibitors Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Non-selective PDE Inhibitors Sales by Country (2021-2026) & (K Units)
Table 35. Americas Non-selective PDE Inhibitors Sales Market Share by Country (2021-2026)
Table 36. Americas Non-selective PDE Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Non-selective PDE Inhibitors Sales by Type (2021-2026) & (K Units)
Table 38. Americas Non-selective PDE Inhibitors Sales by Application (2021-2026) & (K Units)
Table 39. APAC Non-selective PDE Inhibitors Sales by Region (2021-2026) & (K Units)
Table 40. APAC Non-selective PDE Inhibitors Sales Market Share by Region (2021-2026)
Table 41. APAC Non-selective PDE Inhibitors Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Non-selective PDE Inhibitors Sales by Type (2021-2026) & (K Units)
Table 43. APAC Non-selective PDE Inhibitors Sales by Application (2021-2026) & (K Units)
Table 44. Europe Non-selective PDE Inhibitors Sales by Country (2021-2026) & (K Units)
Table 45. Europe Non-selective PDE Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Non-selective PDE Inhibitors Sales by Type (2021-2026) & (K Units)
Table 47. Europe Non-selective PDE Inhibitors Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Non-selective PDE Inhibitors Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Non-selective PDE Inhibitors Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Non-selective PDE Inhibitors Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Non-selective PDE Inhibitors Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Non-selective PDE Inhibitors
Table 53. Key Market Challenges & Risks of Non-selective PDE Inhibitors
Table 54. Key Industry Trends of Non-selective PDE Inhibitors
Table 55. Non-selective PDE Inhibitors Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Non-selective PDE Inhibitors Distributors List
Table 58. Non-selective PDE Inhibitors Customer List
Table 59. Global Non-selective PDE Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Non-selective PDE Inhibitors Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Non-selective PDE Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Non-selective PDE Inhibitors Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Non-selective PDE Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Non-selective PDE Inhibitors Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Non-selective PDE Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Non-selective PDE Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Non-selective PDE Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Non-selective PDE Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Non-selective PDE Inhibitors Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Non-selective PDE Inhibitors Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Non-selective PDE Inhibitors Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Non-selective PDE Inhibitors Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Kyorin Holdings Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 74. Kyorin Holdings Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 75. Kyorin Holdings Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Kyorin Holdings Main Business
Table 77. Kyorin Holdings Latest Developments
Table 78. Senju Pharmaceutical Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 79. Senju Pharmaceutical Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 80. Senju Pharmaceutical Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Senju Pharmaceutical Main Business
Table 82. Senju Pharmaceutical Latest Developments
Table 83. Handok Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 84. Handok Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 85. Handok Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Handok Main Business
Table 87. Handok Latest Developments
Table 88. Endo International Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 89. Endo International Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 90. Endo International Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Endo International Main Business
Table 92. Endo International Latest Developments
Table 93. iNova Pharmaceuticals Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 94. iNova Pharmaceuticals Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 95. iNova Pharmaceuticals Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. iNova Pharmaceuticals Main Business
Table 97. iNova Pharmaceuticals Latest Developments
Table 98. Alembic Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 99. Alembic Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 100. Alembic Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Alembic Main Business
Table 102. Alembic Latest Developments
Table 103. Mundipharma Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 104. Mundipharma Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 105. Mundipharma Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Mundipharma Main Business
Table 107. Mundipharma Latest Developments
Table 108. Mitsubishi Tanabe Pharma Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 109. Mitsubishi Tanabe Pharma Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 110. Mitsubishi Tanabe Pharma Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Mitsubishi Tanabe Pharma Main Business
Table 112. Mitsubishi Tanabe Pharma Latest Developments
Table 113. Glenmark Pharmaceuticals Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 114. Glenmark Pharmaceuticals Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 115. Glenmark Pharmaceuticals Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Glenmark Pharmaceuticals Main Business
Table 117. Glenmark Pharmaceuticals Latest Developments
Table 118. Reyoung Pharmaceutical Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 119. Reyoung Pharmaceutical Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 120. Reyoung Pharmaceutical Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Reyoung Pharmaceutical Main Business
Table 122. Reyoung Pharmaceutical Latest Developments
Table 1. Non-selective PDE Inhibitors Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Non-selective PDE Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Theophylline
Table 4. Major Players of Ibudilast
Table 5. Major Players of Other
Table 6. Global Non-selective PDE Inhibitors Sales by Type (2021-2026) & (K Units)
Table 7. Global Non-selective PDE Inhibitors Sales Market Share by Type (2021-2026)
Table 8. Global Non-selective PDE Inhibitors Revenue by Type (2021-2026) & ($ million)
Table 9. Global Non-selective PDE Inhibitors Revenue Market Share by Type (2021-2026)
Table 10. Global Non-selective PDE Inhibitors Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Non-selective PDE Inhibitors Sale by Application (2021-2026) & (K Units)
Table 12. Global Non-selective PDE Inhibitors Sale Market Share by Application (2021-2026)
Table 13. Global Non-selective PDE Inhibitors Revenue by Application (2021-2026) & ($ million)
Table 14. Global Non-selective PDE Inhibitors Revenue Market Share by Application (2021-2026)
Table 15. Global Non-selective PDE Inhibitors Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Non-selective PDE Inhibitors Sales by Company (2021-2026) & (K Units)
Table 17. Global Non-selective PDE Inhibitors Sales Market Share by Company (2021-2026)
Table 18. Global Non-selective PDE Inhibitors Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Non-selective PDE Inhibitors Revenue Market Share by Company (2021-2026)
Table 20. Global Non-selective PDE Inhibitors Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Non-selective PDE Inhibitors Producing Area Distribution and Sales Area
Table 22. Players Non-selective PDE Inhibitors Products Offered
Table 23. Non-selective PDE Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Non-selective PDE Inhibitors Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Non-selective PDE Inhibitors Sales Market Share Geographic Region (2021-2026)
Table 28. Global Non-selective PDE Inhibitors Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Non-selective PDE Inhibitors Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Non-selective PDE Inhibitors Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Non-selective PDE Inhibitors Sales Market Share by Country/Region (2021-2026)
Table 32. Global Non-selective PDE Inhibitors Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Non-selective PDE Inhibitors Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Non-selective PDE Inhibitors Sales by Country (2021-2026) & (K Units)
Table 35. Americas Non-selective PDE Inhibitors Sales Market Share by Country (2021-2026)
Table 36. Americas Non-selective PDE Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Non-selective PDE Inhibitors Sales by Type (2021-2026) & (K Units)
Table 38. Americas Non-selective PDE Inhibitors Sales by Application (2021-2026) & (K Units)
Table 39. APAC Non-selective PDE Inhibitors Sales by Region (2021-2026) & (K Units)
Table 40. APAC Non-selective PDE Inhibitors Sales Market Share by Region (2021-2026)
Table 41. APAC Non-selective PDE Inhibitors Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Non-selective PDE Inhibitors Sales by Type (2021-2026) & (K Units)
Table 43. APAC Non-selective PDE Inhibitors Sales by Application (2021-2026) & (K Units)
Table 44. Europe Non-selective PDE Inhibitors Sales by Country (2021-2026) & (K Units)
Table 45. Europe Non-selective PDE Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Non-selective PDE Inhibitors Sales by Type (2021-2026) & (K Units)
Table 47. Europe Non-selective PDE Inhibitors Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Non-selective PDE Inhibitors Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Non-selective PDE Inhibitors Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Non-selective PDE Inhibitors Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Non-selective PDE Inhibitors Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Non-selective PDE Inhibitors
Table 53. Key Market Challenges & Risks of Non-selective PDE Inhibitors
Table 54. Key Industry Trends of Non-selective PDE Inhibitors
Table 55. Non-selective PDE Inhibitors Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Non-selective PDE Inhibitors Distributors List
Table 58. Non-selective PDE Inhibitors Customer List
Table 59. Global Non-selective PDE Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Non-selective PDE Inhibitors Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Non-selective PDE Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Non-selective PDE Inhibitors Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Non-selective PDE Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Non-selective PDE Inhibitors Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Non-selective PDE Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Non-selective PDE Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Non-selective PDE Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Non-selective PDE Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Non-selective PDE Inhibitors Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Non-selective PDE Inhibitors Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Non-selective PDE Inhibitors Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Non-selective PDE Inhibitors Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Kyorin Holdings Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 74. Kyorin Holdings Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 75. Kyorin Holdings Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Kyorin Holdings Main Business
Table 77. Kyorin Holdings Latest Developments
Table 78. Senju Pharmaceutical Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 79. Senju Pharmaceutical Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 80. Senju Pharmaceutical Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Senju Pharmaceutical Main Business
Table 82. Senju Pharmaceutical Latest Developments
Table 83. Handok Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 84. Handok Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 85. Handok Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Handok Main Business
Table 87. Handok Latest Developments
Table 88. Endo International Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 89. Endo International Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 90. Endo International Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Endo International Main Business
Table 92. Endo International Latest Developments
Table 93. iNova Pharmaceuticals Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 94. iNova Pharmaceuticals Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 95. iNova Pharmaceuticals Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. iNova Pharmaceuticals Main Business
Table 97. iNova Pharmaceuticals Latest Developments
Table 98. Alembic Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 99. Alembic Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 100. Alembic Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Alembic Main Business
Table 102. Alembic Latest Developments
Table 103. Mundipharma Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 104. Mundipharma Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 105. Mundipharma Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Mundipharma Main Business
Table 107. Mundipharma Latest Developments
Table 108. Mitsubishi Tanabe Pharma Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 109. Mitsubishi Tanabe Pharma Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 110. Mitsubishi Tanabe Pharma Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Mitsubishi Tanabe Pharma Main Business
Table 112. Mitsubishi Tanabe Pharma Latest Developments
Table 113. Glenmark Pharmaceuticals Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 114. Glenmark Pharmaceuticals Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 115. Glenmark Pharmaceuticals Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Glenmark Pharmaceuticals Main Business
Table 117. Glenmark Pharmaceuticals Latest Developments
Table 118. Reyoung Pharmaceutical Basic Information, Non-selective PDE Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 119. Reyoung Pharmaceutical Non-selective PDE Inhibitors Product Portfolios and Specifications
Table 120. Reyoung Pharmaceutical Non-selective PDE Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Reyoung Pharmaceutical Main Business
Table 122. Reyoung Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Non-selective PDE Inhibitors
Figure 2. Non-selective PDE Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Non-selective PDE Inhibitors Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Non-selective PDE Inhibitors Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Non-selective PDE Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Non-selective PDE Inhibitors Sales Market Share by Country/Region (2025)
Figure 10. Non-selective PDE Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Theophylline
Figure 12. Product Picture of Ibudilast
Figure 13. Product Picture of Other
Figure 14. Global Non-selective PDE Inhibitors Sales Market Share by Type in 2026
Figure 15. Global Non-selective PDE Inhibitors Revenue Market Share by Type (2021-2026)
Figure 16. Non-selective PDE Inhibitors Consumed in Hospital
Figure 17. Global Non-selective PDE Inhibitors Market: Hospital (2021-2026) & (K Units)
Figure 18. Non-selective PDE Inhibitors Consumed in Clinic
Figure 19. Global Non-selective PDE Inhibitors Market: Clinic (2021-2026) & (K Units)
Figure 20. Non-selective PDE Inhibitors Consumed in Others
Figure 21. Global Non-selective PDE Inhibitors Market: Others (2021-2026) & (K Units)
Figure 22. Global Non-selective PDE Inhibitors Sale Market Share by Application (2025)
Figure 23. Global Non-selective PDE Inhibitors Revenue Market Share by Application in 2026
Figure 24. Non-selective PDE Inhibitors Sales by Company in 2026 (K Units)
Figure 25. Global Non-selective PDE Inhibitors Sales Market Share by Company in 2026
Figure 26. Non-selective PDE Inhibitors Revenue by Company in 2026 ($ millions)
Figure 27. Global Non-selective PDE Inhibitors Revenue Market Share by Company in 2026
Figure 28. Global Non-selective PDE Inhibitors Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Non-selective PDE Inhibitors Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Non-selective PDE Inhibitors Sales 2021-2026 (K Units)
Figure 31. Americas Non-selective PDE Inhibitors Revenue 2021-2026 ($ millions)
Figure 32. APAC Non-selective PDE Inhibitors Sales 2021-2026 (K Units)
Figure 33. APAC Non-selective PDE Inhibitors Revenue 2021-2026 ($ millions)
Figure 34. Europe Non-selective PDE Inhibitors Sales 2021-2026 (K Units)
Figure 35. Europe Non-selective PDE Inhibitors Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Non-selective PDE Inhibitors Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa Non-selective PDE Inhibitors Revenue 2021-2026 ($ millions)
Figure 38. Americas Non-selective PDE Inhibitors Sales Market Share by Country in 2026
Figure 39. Americas Non-selective PDE Inhibitors Revenue Market Share by Country (2021-2026)
Figure 40. Americas Non-selective PDE Inhibitors Sales Market Share by Type (2021-2026)
Figure 41. Americas Non-selective PDE Inhibitors Sales Market Share by Application (2021-2026)
Figure 42. United States Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Non-selective PDE Inhibitors Sales Market Share by Region in 2026
Figure 47. APAC Non-selective PDE Inhibitors Revenue Market Share by Region (2021-2026)
Figure 48. APAC Non-selective PDE Inhibitors Sales Market Share by Type (2021-2026)
Figure 49. APAC Non-selective PDE Inhibitors Sales Market Share by Application (2021-2026)
Figure 50. China Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 54. India Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Non-selective PDE Inhibitors Sales Market Share by Country in 2026
Figure 58. Europe Non-selective PDE Inhibitors Revenue Market Share by Country (2021-2026)
Figure 59. Europe Non-selective PDE Inhibitors Sales Market Share by Type (2021-2026)
Figure 60. Europe Non-selective PDE Inhibitors Sales Market Share by Application (2021-2026)
Figure 61. Germany Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 62. France Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Non-selective PDE Inhibitors Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Non-selective PDE Inhibitors Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Non-selective PDE Inhibitors Sales Market Share by Application (2021-2026)
Figure 69. Egypt Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Non-selective PDE Inhibitors in 2026
Figure 75. Manufacturing Process Analysis of Non-selective PDE Inhibitors
Figure 76. Industry Chain Structure of Non-selective PDE Inhibitors
Figure 77. Channels of Distribution
Figure 78. Global Non-selective PDE Inhibitors Sales Market Forecast by Region (2027-2032)
Figure 79. Global Non-selective PDE Inhibitors Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Non-selective PDE Inhibitors Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Non-selective PDE Inhibitors Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Non-selective PDE Inhibitors Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Non-selective PDE Inhibitors Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Non-selective PDE Inhibitors
Figure 2. Non-selective PDE Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Non-selective PDE Inhibitors Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Non-selective PDE Inhibitors Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Non-selective PDE Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Non-selective PDE Inhibitors Sales Market Share by Country/Region (2025)
Figure 10. Non-selective PDE Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Theophylline
Figure 12. Product Picture of Ibudilast
Figure 13. Product Picture of Other
Figure 14. Global Non-selective PDE Inhibitors Sales Market Share by Type in 2026
Figure 15. Global Non-selective PDE Inhibitors Revenue Market Share by Type (2021-2026)
Figure 16. Non-selective PDE Inhibitors Consumed in Hospital
Figure 17. Global Non-selective PDE Inhibitors Market: Hospital (2021-2026) & (K Units)
Figure 18. Non-selective PDE Inhibitors Consumed in Clinic
Figure 19. Global Non-selective PDE Inhibitors Market: Clinic (2021-2026) & (K Units)
Figure 20. Non-selective PDE Inhibitors Consumed in Others
Figure 21. Global Non-selective PDE Inhibitors Market: Others (2021-2026) & (K Units)
Figure 22. Global Non-selective PDE Inhibitors Sale Market Share by Application (2025)
Figure 23. Global Non-selective PDE Inhibitors Revenue Market Share by Application in 2026
Figure 24. Non-selective PDE Inhibitors Sales by Company in 2026 (K Units)
Figure 25. Global Non-selective PDE Inhibitors Sales Market Share by Company in 2026
Figure 26. Non-selective PDE Inhibitors Revenue by Company in 2026 ($ millions)
Figure 27. Global Non-selective PDE Inhibitors Revenue Market Share by Company in 2026
Figure 28. Global Non-selective PDE Inhibitors Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Non-selective PDE Inhibitors Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Non-selective PDE Inhibitors Sales 2021-2026 (K Units)
Figure 31. Americas Non-selective PDE Inhibitors Revenue 2021-2026 ($ millions)
Figure 32. APAC Non-selective PDE Inhibitors Sales 2021-2026 (K Units)
Figure 33. APAC Non-selective PDE Inhibitors Revenue 2021-2026 ($ millions)
Figure 34. Europe Non-selective PDE Inhibitors Sales 2021-2026 (K Units)
Figure 35. Europe Non-selective PDE Inhibitors Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Non-selective PDE Inhibitors Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa Non-selective PDE Inhibitors Revenue 2021-2026 ($ millions)
Figure 38. Americas Non-selective PDE Inhibitors Sales Market Share by Country in 2026
Figure 39. Americas Non-selective PDE Inhibitors Revenue Market Share by Country (2021-2026)
Figure 40. Americas Non-selective PDE Inhibitors Sales Market Share by Type (2021-2026)
Figure 41. Americas Non-selective PDE Inhibitors Sales Market Share by Application (2021-2026)
Figure 42. United States Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Non-selective PDE Inhibitors Sales Market Share by Region in 2026
Figure 47. APAC Non-selective PDE Inhibitors Revenue Market Share by Region (2021-2026)
Figure 48. APAC Non-selective PDE Inhibitors Sales Market Share by Type (2021-2026)
Figure 49. APAC Non-selective PDE Inhibitors Sales Market Share by Application (2021-2026)
Figure 50. China Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 54. India Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Non-selective PDE Inhibitors Sales Market Share by Country in 2026
Figure 58. Europe Non-selective PDE Inhibitors Revenue Market Share by Country (2021-2026)
Figure 59. Europe Non-selective PDE Inhibitors Sales Market Share by Type (2021-2026)
Figure 60. Europe Non-selective PDE Inhibitors Sales Market Share by Application (2021-2026)
Figure 61. Germany Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 62. France Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Non-selective PDE Inhibitors Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Non-selective PDE Inhibitors Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Non-selective PDE Inhibitors Sales Market Share by Application (2021-2026)
Figure 69. Egypt Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Non-selective PDE Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Non-selective PDE Inhibitors in 2026
Figure 75. Manufacturing Process Analysis of Non-selective PDE Inhibitors
Figure 76. Industry Chain Structure of Non-selective PDE Inhibitors
Figure 77. Channels of Distribution
Figure 78. Global Non-selective PDE Inhibitors Sales Market Forecast by Region (2027-2032)
Figure 79. Global Non-selective PDE Inhibitors Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Non-selective PDE Inhibitors Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Non-selective PDE Inhibitors Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Non-selective PDE Inhibitors Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Non-selective PDE Inhibitors Revenue Market Share Forecast by Application (2027-2032)
